Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) CEO Sath Shukla sold 14,800 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $1.32, for a total value of $19,536.00. Following the completion of the sale, the chief executive officer now directly owns 1,161,207 shares of the company’s stock, valued at $1,532,793.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Sath Shukla also recently made the following trade(s):
- On Monday, August 5th, Sath Shukla sold 17,641 shares of Spero Therapeutics stock. The shares were sold at an average price of $1.31, for a total transaction of $23,109.71.
Spero Therapeutics Stock Performance
Spero Therapeutics stock traded down $0.07 during trading hours on Tuesday, reaching $1.27. 323,154 shares of the stock were exchanged, compared to its average volume of 222,742. Spero Therapeutics, Inc. has a 52-week low of $0.99 and a 52-week high of $1.89. The stock has a market cap of $68.57 million, a P/E ratio of 2.95 and a beta of 0.63. The firm’s 50 day moving average is $1.38 and its 200 day moving average is $1.51.
Analyst Ratings Changes
Several research analysts have issued reports on SPRO shares. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Spero Therapeutics in a research report on Tuesday. TD Cowen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday.
Check Out Our Latest Analysis on Spero Therapeutics
Hedge Funds Weigh In On Spero Therapeutics
Large investors have recently modified their holdings of the business. ADAR1 Capital Management LLC acquired a new position in Spero Therapeutics during the fourth quarter worth about $1,570,000. Vanguard Group Inc. boosted its stake in shares of Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after acquiring an additional 9,675 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after acquiring an additional 418,742 shares during the period. Murchinson Ltd. increased its stake in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Spero Therapeutics during the first quarter worth $31,000. 25.60% of the stock is owned by hedge funds and other institutional investors.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Further Reading
- Five stocks we like better than Spero Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- 3 Stocks to Consider Buying in October
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.